PMID

Data

Article Title

Organization

Comprehensive analysis of kinase inhibitor selectivity.

Ambit Biosciences

Discovery of a Novel Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2) and Cyclin-Dependent Kinase 4 (CDK4) Dual Inhibitor for the Treatment of Triple-Negative Breast Cancer.

China Pharmaceutical University

Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts.

Hefei University of Technology

3,5,7-Substituted Pyrazolo[4,3-

Palack£

Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13.

Jinan University

Current progress and novel strategies that target CDK12 for drug discovery.

West China Hospital

Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors.

Jinan University

Discovery of Dual CDK6/PIM1 Inhibitors with a Novel Structure, High Potency, and Favorable Druggability for the Treatment of Acute Myeloid Leukemia.

China Pharmaceutical University

Discovery of

China Pharmaceutical University

Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing sarcoma.

Harvard Medical School

Synthetic Lethality through the Lens of Medicinal Chemistry.

Istituto Italiano Di Tecnologia

Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures.

The First Affiliated Hospital of Zhengzhou University

Discovery of MFH290: A Potent and Highly Selective Covalent Inhibitor for Cyclin-Dependent Kinase 12/13.

Harvard Medical School

CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success?

Lebanese American University

Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019).

Eli Lilly

Discovery of 4

TBA

Discovery of 3-Benzyl-1-( trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea Derivatives as Novel and Selective Cyclin-Dependent Kinase 12 (CDK12) Inhibitors.

Takeda Pharmaceutical